SCHEMBL13429239

SCHEMBL13429239

O=c1cc(Oc2cccc(-c3cccc(CN4CCOCC4)c3)c2)c2ccccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
TLR8 Q9NR97 1/20 0.48
TLR7 Q9NYK1 1/20 0.48
PARP1 P09874 3/20 0.47
HTR1A P08908 3/20 0.46
DRD2 P14416 3/20 0.46
CYP11B1 P15538 1/20 0.44
PSMB8 P28062 1/20 0.44
CHRM3 P20309 1/20 0.42
TNKS O95271 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429232 0.83 KIF11 (0.47) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL3225063 0.82 ABL1 (0.44)
SCHEMBL13429235 0.81 CNR2 (0.51) TLR8TLR7MAPTCNR2
SCHEMBL13429255 0.79 ALDH1A1 (0.46) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL13429032 0.78 KDR (0.48) KDM4EALDH1A1PARP1GAAALOX15
SCHEMBL13429161 0.78 HPGD (0.54) KDM4EALDH1A1HPGDHTTNPC1
SCHEMBL7933316 0.78 CNR1 (0.47) KDM4EALDH1A1HPGDHTTTLR8
SCHEMBL13429347 0.74 LTA4H (0.43) TLR7
SCHEMBL3217295 0.74 HPGD (0.46) KDM4EALDH1A1HPGDHTTPARP1
SCHEMBL13429152 0.73 HPGD (0.43) KDM4EALDH1A1HPGDHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA KDM4E 728/4885ALDH1A1 2884/4885HPGD 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.